⏱️5 min read | New research points to HTT1a, a toxic shortened form of huntingtin, as a key driver of disease and a promising therapeutic target in HD.

A new Phase 1 study is testing SRP-1005, a huntingtin-lowering therapy given by injection under the skin. It’s early days, but this approach could add an important new arrow to the HD drug development quiver.

⏱️ 5 min read | Announcing the 2026 HDBuzz Prize for Young Science Writers – sponsored by the Hereditary Disease Foundation!